The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1346
September 6, 2010
View Complete Issue         Table of Contents 2019 
Natazia - A New Oral Contraceptive
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Natazia - A New Oral Contraceptive
September 6, 2010 (Issue: 1346)
The FDA has approved the marketing of Natazia (Bayer), a 4-phase oral contraceptive containing the estrogen estradiol valerate and the progestin dienogest, both used for the first time in the US for this indication.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Natazia - A New Oral Contraceptive
Article code: 1346d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.